Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26317513 | 0.85 | TSHR (0.43) | HRH2HRH1PIK3CD | |
| SCHEMBL27979621 | 0.85 | — | — | |
| SCHEMBL15832599 | 0.85 | HRH2 (0.52) | HRH2HRH1KDM4EPIK3CD | |
| SCHEMBL19400534 | 0.85 | HRH2 (0.42) | HRH2HRH1PIK3CD | |
| SCHEMBL770801 | 0.83 | HRH2 (0.41) | HRH2HRH1PIK3CD | |
| SCHEMBL26073702 | 0.83 | HRH2 (0.41) | HRH2HRH1PIK3CD | |
| SCHEMBL12283671 | 0.82 | ALDH1A1 (0.56) | KDM4E | |
| SCHEMBL7946318 | 0.80 | HRH2 (0.45) | HRH2HRH1PIK3CD | |
| SCHEMBL25963051 | 0.80 | HRH2 (0.40) | HRH2HRH1KDM4EPIK3CDCHRM1 | |
| SCHEMBL25567950 | 0.80 | HRH2 (0.45) | HRH2HRH1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| WO-2014008458-A2 | N-SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731987-B2 | Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof | EGLN3, EGLN2, EGLN1 | HRH2 293/4885HRH1 210/4885KDM4E 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.